FMR1 GENE POLYMORPHISM IN POLYCYSTIC OVARY SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the frequency of different alleles of highly polymorphic CGG repeat in the FMR1 gene in patients with polycystic ovary syndrome (POS) and their relationship to the functional state of the reproductive system. Subjects and methods. The CGG-repeat alleles in the FMR1 gene were determined in 115patients with POS, by using a methylation-specific polymerase chain reaction (MS-PCR) assay, followed by a fragment analysis of the products conjugated with the fluorescence dye FAM. Results. The range (according to the results of previous investigations) of 28-36 CGG trinucleotide repeats in the FMR1 gene was taken as a conventional normal value in reference to the ovarian reserve in a Russian population. With this in mind, the investigators identified 3 groups of patients: who had a short (<28) allele a, who had a normal (28-36) allele b and who had a long (>36) allele c. There were 5 subgenotypes: aa in 7% of the patients; ab in 22.8%; bb in 50.9%; be in 14.9%; and ac in 4.4%>. The length of CGGrepeats in the FMR1 gene were in the reference values (bb) in 50.9% of the patients with POS; accordingly 49.1% had abnormal alleles (a and c). In accordance with the subgenotypes, there were 3 study groups: 1) 58 (50.9%) patients (bb); 2) 43 (37.7%) patients with one abnormal (short or long) allele (be, ab), and 3) 13 (11.4%) with two abnormal alleles (ac, aa). There was a two-fold increase in the incidence of amenorrhea in patients in Group 3 as compared to those in Groups 1 and (29% versus 13 and 15%, respectively; p<0.05). The mean level of anti-Mullerian hormone increased with abnormal alleles; in Group 3, it was significantly higher than in Groups 1 and 2(17.8+5.4pg/ml versus 12.1±2.6and 14.3±9.8pg/ml, respectively; p < 0.05). Longer CGG repeats were detectable in patients with infertility versus those with preserved fertility (32±4.08 versus 20.5±1.71 (1-CGG) and 33±5.04 versus 24±3.57(2-CGG) (p < 0.001). Conclusion. Regardless of the phenotype of POS, every two patients with this condition are found to have the abnormal number of CGG repeats in the FMR1 gene, which is associated with severer ovulatory dysfunction. The high rate of the presentation of abnormal alleles in the FMR1 gene, which is comparable with that in POS, may suggest that there is a similarity of molecular genetic changes in the pathogenesis of impaired folliculogenesis in these conditions.

Full Text

Restricted Access

About the authors

G. I Tabeeva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: bambine@mail.ru
MD, PhD, researcher at the Department of Gynecological Endocrinology Moscow 117997, Ac. Oparina str. 4, Russia

Yu. I Nemova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: j_nemova@hoonail.com
graduate student of department of gynecological endocrinology Moscow 117997, Ac. Oparina str. 4, Russia

A. A Naidukova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: aleeshla@mail.ru
post-graduate department of gynecological endocrinology Moscow 117997, Ac. Oparina str. 4, Russia

E. B Kuznetsova

I.M. Sechenov First Moscow State Medical University

Email: kuznetsova.k@bk.ru
Ph.D., Leading Researcher, Laboratory of Human Molecular Genetics Moscow 119048, Trubetskaya str. 8, bid. 2, Russia

D. B Zaletaev

I.M. Sechenov First Moscow State Medical University

Ph.D., Professor, Head of Laboratory of Human Molecular Genetics Moscow 119048, Trubetskaya str. 8, bid. 2, Russia

G. E Chernukha

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

MD, Professor, Head of the Department of Gynecological Endocrinology Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Fauser В.C., Tarlatzis В.С., Rebar R.W., Legro R.S., Balen A.H., Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 2012; 97(1): 28-38. e25.
  2. Legro R.S., Modi B.P., Strauss J.F., McAllister J.M., 3rd. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol. Metab. 2015; 26(3): 118-24. doi: 10.1016/j.tem.2014.12.004.
  3. Gleicher N., Weghofer A., Barad D.H. Effects of race/ethnicity on triple CGG counts on FMR1 gene in infertile women and egg donors. Reprod. Biomed. Online. 2010; 20(4): 485-91.
  4. Hoffman G.E., Le W.W., Entezam A., Otsuka N., Tong Z.B., Nelson L. et al. Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency. J. Histochem. Cytochem. 2012; 60(6): 439-56.
  5. Lu C., Lin L., Tan H., Wu H., Sherman S.L., Gao F. et al. Fragile X permutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum. Mol. Genet. 2012; 21(23): 5039-47.
  6. Conway G.S. Premature ovarian failure and FMR1 gene mutations: an update. Ann. Endocrinol. (Paris). 2010; 71(3): 215-7.
  7. Gleicher N., Weghofer A., Lee I.H., Barad D.H. FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS One. 2010; 5(12): ЄІ5303.
  8. Barad D.H., Weghofer A., Goyal A., Gleicher N. Further refinement in defining the effect of heterozygous-abnormal egg counts on the FMR1 (Fragile X) gene: definition of a distinct subgroup of PCOS patient, based on norma/low genotype. Fertil. Steril. 2009; 92(3, Suppl.): S105.
  9. Rotterdam ESHRE/ASMR-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 19-26.
  10. Shamilova N.N., Marchenko L.A., Dolgushina N. V., ZaletaevD. V., Sukhikh G. T The role of genetic and autoimmune factors in premature ovarian failure. J. Assist. Reprod. Genet. 2013; 30(5): 617-22.
  11. Gleicher N., Weghover A., Oktay K., Barad D.H. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? Acta Obstet. Gynecol. Scand. 2009; 88(9): 1024-30.
  12. Spath M.A., Feuch T.B., Allen E.G., SmitsA.P., YntemaH.G., van Kessei A.G. et al. Intra-indinidual stability over time of standardardized anti- Mullerian hormone in FMR1 premutation carries. Hum. Reprod. 2011; 26(8): 2185- 91.
  13. Choe S.A., Кіт K.C., Lee J.Y., Кіт C.H., Hwang D., Jee B.C. The relation between the number of CGG repeats and serum level of anti-Mullerian hormone in women without FMR1 premutation. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 169(2): 275-8.
  14. DeGeyter C., M’Rabet N., DeGeyter J., Ziircher S., Moffat R., Bosch N. et al. Similar prevalence of expanded CGG repeat length sinthe fragile X mental retardation I gene among infertile women and among women with provenfertility: a prospective study. Genet. Med. 2014; 16(5): 374-8.
  15. Kline J., Kinney A., Kelly A., Reuss M.L., Levin B. Predictors of antral follicle count during the reproductive years. Hum. Reprod. 2005; 20(8): 2179-89.
  16. Rohr J., Allen E.G., Charen K., Giles J., He W., Dominguez C. et al. Anti- Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum. Reprod. 2008; 23: 1220-5.
  17. Pastore L.M., Young S.L., Baker V.L., Karns L.B., Williams C.D., Silverman L.M. Elevated prevalence of 35-44 FMR1 trinucleotide repeats in women with diminished ovarian reserve. Reprod. Sci. 2012; 19(11): 1226-31.
  18. Gleicher N., Weghofer A., Barad D.H. Ovarian reserve determinations suggest new function of FMR1 (fragile X) gene in regulating ovarian aging. Reprod. Biomed. Online. 2010; 20(6): 768-75.
  19. Gleicher N., Kushnir V.A., Weghofer A., Barad D.H. How the FMR1 gene became relevant to female fertility and reproductive medicine. Front. Genet. 2014; 5: 284.
  20. Ванян З.Э. Клинико-диагностическое значение аутоиммунных и генетических факторов при “бедном” овариальном ответе на стимуляцию суперовуляции в программах вспомогательных репродуктивных технологий: автореф. дисс.. канд. мед. наук. М.; 2015. 27с.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies